XERS
Xeris Biopharma Holdings, Inc. (XERS) 10Y Growth Potential Analysis (2026)
Overall Score
Growth Runway
Xeris has a large gross margin base (83.3%) and positive operating cash flow, supporting reinvestment capacity.
Revenue per share is $1.94 with a price-to-sales ratio of 4.43, implying the market still prices in meaningful growth.
However, the company remains unprofitable on a net basis with a -5.1% net margin and negative earnings yield, limiting the quality of the growth story.
Profitability And Cash Generation
Operating margin is positive at 10.9% and operating cash flow margin is 16.9%, showing the core business can generate cash.
Free cash flow is positive, but conversion is still modest relative to valuation with a 26.8x price-to-free-cash-flow ratio.
Net income remains negative and return on equity is deeply negative, indicating profitability is not yet durable.
Balance Sheet And Dilution Risk
Current ratio of 1.45 and quick ratio of 1.02 suggest near-term liquidity is adequate.
Debt remains meaningful, with debt-to-capital above 1.0 and interest coverage only 1.3x, which keeps leverage risk elevated.
Negative book value and weak solvency metrics indicate the capital structure still carries risk.
Execution And Reinvestment Efficiency
Return on invested capital is 12.5% and return on capital employed is 16.5%, showing some efficiency in deployed capital.
Capex is light relative to operating cash flow, leaving room for commercial and product investment.
That said, inventory days are very high and the cash conversion cycle is long, which reduces reinvestment efficiency.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Xeris Biopharma Holdings, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

